Radionuclide-based theranostics — a promising strategy for lung cancer

Zhu, Tianxing; Hsu, Jessica C.; Guo, Jingpei; Chen, Wei-Yu; Cai, Weibo; Wang, Kai

doi:10.1007/s00259-023-06174-8

Cited by 2 publications

(3 citation statements)

References 220 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer can be divided into two major groups nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for about 80% to 85% of all lung cancers, while the figure for SCLC is about 15% . The International Association for the Study of Lung Cancer reports five-year survival rates for stage IIIA, IIIB, IIIC, and IV NSCLC of 36%, 26%, 13%, and 6%, respectively .…”

Section: Advances In Theoretical Research On Cancer Vaccinesmentioning

confidence: 99%

“…NSCLC accounts for about 80% to 85% of all lung cancers, while the figure for SCLC is about 15%. 219 The International Association for the Study of Lung Cancer reports five-year survival rates for stage IIIA, IIIB, IIIC, and IV NSCLC of 36%, 26%, 13%, and 6%, respectively. 21 Over the past two decades, insights into the immune system and tumor-expressed antigens, as well as improvements in immune adjuvants and delivery systems, have promoted the progress of lung cancer vaccines.…”

Section: Advances In Theoretical Research On Cancer Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Advances in Cancer Vaccine Research

Liu,

Xiao,

Zhang

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

The use of cancer vaccines is considered a promising therapeutic strategy in clinical oncology, which is achieved by stimulating antitumor immunity with tumor antigens delivered in the form of cells, peptides, viruses, and nucleic acids. The ideal cancer vaccine has many advantages, including low toxicity, specificity, and induction of persistent immune memory to overcome tumor heterogeneity and reverse the immunosuppressive microenvironment. Many therapeutic vaccines have entered clinical trials for a variety of cancers, including melanoma, breast cancer, lung cancer, and others. However, many challenges, including single antigen targeting, weak immunogenicity, off-target effects, and impaired immune response, have hindered their broad clinical translation. In this review, we introduce the principle of action, components (including antigens and adjuvants), and classification (according to applicable objects and preparation methods) of cancer vaccines, summarize the delivery methods of cancer vaccines, and review the clinical and theoretical research progress of cancer vaccines. We also present new insights into cancer vaccine technologies, platforms, and applications as well as an understanding of potential next-generation preventive and therapeutic vaccine technologies, providing a broader perspective for future vaccine design.

show abstract

Section: Advances In Theoretical Research On Cancer Vaccinesmentioning

confidence: 99%

Section: Advances In Theoretical Research On Cancer Vaccinesmentioning

confidence: 99%

Advances in Cancer Vaccine Research

Liu,

Xiao,

Zhang

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…For instance, image-guided RT helps locate and analyze tumor spread [ 10 ]. Other promising areas of research involve combining immunotherapy with RT [ 11 ], radionuclide-based treatment [ 12 ], concurrent chemoradiotherapy, and targeted therapy. Additionally, the treatment regimen for NSCLC often requires systemic therapy and a combination of multiple treatments.…”

Section: Introductionmentioning

confidence: 99%

Nano-Assisted Radiotherapy Strategies: New Opportunities for Treatment of Non-Small Cell Lung Cancer

Zhao,

Li,

Shen

et al. 2024

Research

View full text Add to dashboard Cite

Lung cancer is the second most commonly diagnosed cancer and a leading cause of cancer-related death, with non-small cell lung cancer (NSCLC) being the most prevalent type. Over 70% of lung cancer patients require radiotherapy (RT), which operates through direct and indirect mechanisms to treat cancer. However, RT can damage healthy tissues and encounter radiological resistance, making it crucial to enhance its precision to optimize treatment outcomes, minimize side effects, and overcome radioresistance. Integrating nanotechnology into RT presents a promising method to increase its efficacy. This review explores various nano-assisted RT strategies aimed at achieving precision treatment. These include using nanomaterials as radiosensitizers, applying nanotechnology to modify the tumor microenvironment, and employing nano-based radioprotectors and radiation-treated cell products for indirect cancer RT. We also explore recent advancements in nano-assisted RT for NSCLC, such as biomimetic targeting that alters mesenchymal stromal cells, magnetic targeting strategies, and nanosensitization with high-atomic number nanomaterials. Finally, we address the existing challenges and future directions of precision RT using nanotechnology, highlighting its potential clinical applications.

show abstract

Radionuclide-based theranostics — a promising strategy for lung cancer

Cited by 2 publications

References 220 publications

Advances in Cancer Vaccine Research

Advances in Cancer Vaccine Research

Nano-Assisted Radiotherapy Strategies: New Opportunities for Treatment of Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About